Legacy Flip




		
	        

	        	        		637article: Alternative Payment Models and the Future of Personalized Medicine	        


	        
	        

	        	        		637article: The Fourth Annual World Cutaneous Malignancies Congress	        


	        
	        

	        	        		637article: Care Pathway for NSCLC Cuts Chemotherapy Charges	        


	        
	        

	        	        		637article: New CLL-IPI Scoring System Validated as Clinically Applicable	        


	        
	        

	        	        		637article: IDH1 Gene and ATRX Gene Prognostic in Anaplastic Astrocytoma	        


	        
	        

	        	        		637article: Combination Targeted and Immunotherapy Feasible in Advanced Melanoma	        


	        
	        

	        	        		637article: GADOLIN Trial: Obinutuzumab Moves into Indolent Lymphoma	        


	        
	        

	        	        		637article: Molecular Subtype-Specific Therapy in DLBCL	        


	        
	        

	        	        		637article: Leukemia Stem Cell Phenotypes Associated with Outcomes	        


	        
	        

	        	        		637article: Considerations in Genetic Testing	        


	        
	        

	        	        		637article: Sonidegib Responses Improve by Use of Less Stringent Assessment Criteria in BCC	        


	        
	        

	        	        		637article: Case Presentation: Targeted Therapy in Metastatic Melanoma	        


	        
	        

	        	        		637article: Regulatory Processes Slow Application of Genetic Tests	        


	        
	        

	        	        		637article: Predictive Potential of Molecular Biomarkers Promises to Enhance Precision Medicine in Oncology	        


	        
	        

	        	        		637article: Molecular Pathways in Cancer Are Increasingly Being Exploited	        


	        
	        

	        	        		637article: New Methods for Surveillance and Preclinical Modeling Highlight Cancer Biomarker Research	        


	        
	        

	        	        		637article: Genetic Drivers Identified in Premalignancy; Next Step Is Targeting Them for Prevention	        


	        
	        

	        	        		637article: A Genetic-Based Approach to Individualized Prostate Cancer Screening and Treatment	        


	        
	        

	        	        		637article: Challenges in Treating Multiple Myeloma and the Impact of New Oral Oncolytics	        


	        
	        

	        	        		637article: Showcasing the Success of Precision Medicine	        


	        
	        

	        	        		636article: Immunotherapy Makes Headwinds into Liver Cancer	        


	        
	        

	        	        		636article: Targeted and Immunologic Approaches to Brain Metastases	        


	        
	        

	        	        		636article: Treating with Checkpoint Inhibitors—Figure $1 Million per Patient	        


	        
	        

	        	        		636article: Searching for the Tipping Point in Drug Pricing	        


	        
	        

	        	        		636article: ASCO’s Value Initiative: A Case-Based Approach	        


	        
	        

	        	        		636article: Aetna Examines Cost by Site of Service	        


	        
	        

	        	        		636article: Enhanced Reimbursement for Oncology Services Pays for Patient-Centered Care	        


	        
	        

	        	        		636article: Cost-Effectiveness of T-DM1 Examined	        


	        
	        

	        	        		636article: Urine Assays Detect Early Mutations in Patients with Advanced Cancers	        


	        
	        

	        	        		636article: Docetaxel Boosts Survival in Hormone-Naive Metastatic Prostate Cancer	        


	        
	        

	        	        		636article: Bevacizumab Wins Cost-Effectiveness Analysis in First-Line Metastatic Colorectal Cancer	        


	        
	        

	        	        		636article: Adding Radiation to First-Line FOLFOX Reduces Progression of Liver Metastases in Patients with Metastatic Colorectal Cancer	        


	        
	        

	        	        		636article: T-DM1 Not Superior to Standard of Care in First-Line Metastatic Breast Cancer	        


	        
	        

	        	        		636article: Oral Nicotinamide Prevents Common Skin Cancers	        


	        
	        

	        	        		636article: Ibrutinib Reduces Risk of Progression in Previously Treated CLL	        


	        
	        

	        	        		636article: Activating KIR Genes Implicated in Development of MDS	        


	        
	        

	        	        		636article: Genetic Abnormality Pinpointed for Intensive Therapy in Wilms Tumor	        


	        
	        

	        	        		636article: Lenvatinib Warrants Further Study in mRCC	        


	        
	        

	        	        		636article: Elotuzumab, a First-in-Class Monoclonal Antibody Immunotherapy, Improves Outcomes in Patients with Multiple Myeloma	        


	        
	        

	        	        		636article: Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma	        


	        
	        

	        	        		636article: Encouraging Results for Pembrolizumab in Head and Neck Cancer	        


	        
	        

	        	        		636article: ABCs of Immunotherapy	        


	        
	        

	        	        		636article: Pembrolizumab in Colorectal Cancer: Can Benefit Be Predicted?	        


	        
	        

	        	        		636article: Early Data for ANTI–PD-L1 in Urothelial Bladder Cancer	        


	        
	        

	        	        		636article: Sharing the Best of ASCO	        


	        
	        

	        	        		636article: Nivolumab Is Superior to Docetaxel as Second-Line Therapy for Patients with NSCLC	        


	        
	        

	        	        		636article: Clues to Patient Selection for Lenvatinib in Thyroid Cancer	        


	        
	        

	        	        		636article: Biomarkers for Nivolumab	        


	        
	        

	        	        		636article: Immunotherapies Steal the Show at ASCO	        


	        
	        

	        	        		634article: Immunotherapy May Prolong Recurrence-Free Survival in Advanced Ovarian Cancer	        


	        
	        

	        	        		634article: Checkpoint Blockade: Durable Responses in Lung and Kidney Cancers and Metastatic Melanoma	        


	        
	        

	        	        		634article: Case: “Difficult-to-Operate” Basal Cell Carcinoma	        


	        
	        

	        	        		634article: CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Review of the Phase 1 Clinical Trials	        


	        
	        

	        	        		634article: Vaccines for the Treatment of Non–Small Cell Lung Cancer (NSCLC)	        


	        
	        

	        	        		634article: Checkpoint Modulation for Lung Cancer	        


	        
	        

	        	        		634article: Sharing Experiences with Immunotherapy: Call for Case Studies	        


	        
	        

	        	        		633article: ASCO Launches First-Ever Clinical Trial: Aims to Learn from Patients with Advanced Cancer Who Lack Standard Treatment Options	        


	        
	        

	        	        		633article: Genomic Sequencing for Pancreatic Cancer	        


	        
	        

	        	        		633article: PARP Inhibitor and PI3K Inhibitor Combo in Breast and Ovarian Cancers	        


	        
	        

	        	        		633article: DNA Blood Testing May Be an Alternative to Tumor Sampling for Identifying EGFR Mutations	        


	        
	        

	        	        		633article: Case Studies: Incorporating Molecular Biomarkers into Therapy for Breast Cancer Is Fraught with Difficulty	        


	        
	        

	        	        		633article: Case: Former Smoker with Well-Differentiated Adenocarcinoma of the Lung	        


	        
	        

	        	        		633article: The RET Oncogene in Non–Small Cell Lung Cancer: Review of the Current Literature and Directions for the Future	        


	        
	        

	        	        		633article: BRAF Mutations: An Old Oncogene and a New Target in Non–Small Cell Lung Cancer	        


	        
	        

	        	        		633article: Expanding Options for EGFR-Mutant Non–Small Cell Lung Cancer with Afatinib	        


	        
	        

	        	        		633article: Understanding Implications of the Proposed FDA Regulation of Laboratory Developed Tests	        


	        
	        

	        	        		633article: The Increasingly Important Role of Pathology in Oncology Patient Care	        


	        
	        

	        	        		630article: President Obama’s Bet on Personalized Medicine	        


	        
	        

	        	        		630article: NRAS Mutation Impacts Response to Immune Therapies in Melanoma	        


	        
	        

	        	        		630article: PROSTVAC plus Immune Checkpoint Inhibitors: Evidence of Improved Overall Survival in Prostate Cancer	        


	        
	        

	        	        		630article: Cell Cycle Progression Test Impacts Treatment Decisions	        


	        
	        

	        	        		630article: Renal Cell Carcinoma Roundup: Immune checkpoint inhibitors show promise	        


	        
	        

	        	        		630article: PD-L1: Promising MIUC Therapy for cNAC Nonresponders	        


	        
	        

	        	        		630article: Immuno-Oncology Combination Approaches for Lung Cancer	        


	        
	        

	        	        		630article: FDA Approves Opdivo (Nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non–Small Cell Lung Cancer	        


	        
	        

	        	        		630article: The Need for Immunotherapeutic Approaches for Lung Cancer	        


	        
	        

	        	        		630article: The Commercialization Process of Immunotherapies: 
An Interview with Olivier Lesueur and Rachel Laing, PhD
	        


	        
	        

	        	        		630article: Exploring Advances in Immunotherapy	        


	        
	        

	        	        		629article: President Obama’s Bet on Personalized Medicine	        


	        
	        

	        	        		629article: What Is a Navigator?	        


	        
	        

	        	        		629article: No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer	        


	        
	        

	        	        		629article: AR-V7 Predicts Chemotherapy Sensitivity in Metastatic Prostate Cancer	        


	        
	        

	        	        		629article: Cabozantinib in Prostate Cancer Patients with Bone Metastasis	        


	        
	        

	        	        		629article: Biomarkers of the mTOR Pathway in Breast Cancer	        


	        
	        

	        	        		629article: Two Cases of Triple-Hit Lymphoma: A Call for Imperative MYC, BCL2, and BCL6 Testing by FISH in Aggressive Lymphomas	        


	        
	        

	        	        		629article: Confirming Diagnoses and Identifying Biomarkers Linked to Targeted Treatments with the bioT3 Approach	        


	        
	        

	        	        		628article: Bristol-Myers Squibb to Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc	        


	        
	        

	        	        		628article: PD-L1 Inhibitor Pembrolizumab Produces Good Responses in Advanced Gastric Cancer	        


	        
	        

	        	        		628article: Exploring Immune Checkpoint Blockade for Glioblastoma	        


	        
	        

	        	        		628article: Vaccines for Glioblastoma	        


	        
	        

	        	        		628article: Targeting EGFRvIII in Glioblastoma	        


	        
	        

	        	        		628article: Immunotherapy in Glioblastoma, the Most Lethal Form of Brain Cancer	        


	        
	        

	        	        		628article: The Reach of Immunotherapy: Focus on Glioblastoma	        


	        
	        

	        	        		627article: To Regulate or Not to Regulate Laboratory-Developed Tests, That Is the Question	        


	        
	        

	        	        		627article: FACT SHEET: President Obama’s Precision Medicine Initiative	        


	        
	        

	        	        		627article: Basket Trials Based on Genomics Hold Promise	        


	        
	        

	        	        		627article: PARP Inhibitors in Gynecologic Cancer: More Questions Than Answers	        


	        
	        

	        	        		627article: Scientific Exploration of Obesity and Breast Cancer Link	        


	        
	        

	        	        		627article: Genomic Panel Likely to Be Cost-effective in AML	        


	        
	        

	        	        		627article: Personalizing Myeloma Treatment Can Limit the Use of Expensive Drugs